FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer
21st September 2021 Uncategorised 0Cabometyx found to reduce the risk of disease progression or death versus placebo in this patient population
More: FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer
Source: News
